XFOR
NASDAQX4 Pharmaceuticals Inc.
Price$2.59+0.04 (+1.77%)
01:45 PM07:45 PM
News · 26 weeks38+75%
2026-04-192026-10-11
Mix1890d
- Other10(56%)
- SEC Filings5(28%)
- Insider3(17%)
Latest news
25 items- PRX4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion LeadersBOSTON, Oct. 09, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that the Company will host a virtual Investor Day on Thursday, October 29, 2026, from 10:00 a.m. to 12:00 p.m. ET. The Investor Day will feature discussions with X4 Pharmaceuticals management and key opinion leaders on mavorixafor as a potential treatment for chronic neutropenia. Management will review the current status of the Phase 3 4WARD clinical trial and will outline a planned Phase 2 clinical trial of mavorixafor in combination with granulocyte colony-stimulating factor (G-CSF), designed to assess patients' abi
- SECSEC Form 8-K filed by X4 Pharmaceuticals Inc.8-K - X4 Pharmaceuticals, Inc (0001501697) (Filer)
- PRX4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures- Repayment of Existing Loan Facility Completed -- Strengthens Financial Flexibility with Access to Funding for Corporate and Commercial Activities - - Expect Completion of Enrollment in Phase 3 4WARD trial by Year-End 2026 and Topline Data in H1 2028 - BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that it has entered into a senior secured term loan facility of up to $150 million with K2 HealthVentures LLC ("K2HV"), an alternative investment firm that provides flexible, long-term financing solutions in the life sciences and healthcare industries. The K2HV facilit
- SECAmendment: SEC Form SCHEDULE 13G/A filed by X4 Pharmaceuticals Inc.SCHEDULE 13G/A - X4 Pharmaceuticals, Inc (0001501697) (Subject)
- INSIDERSEC Form 4 filed by X4 Pharmaceuticals Inc.4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
- SECSEC Form 144 filed by X4 Pharmaceuticals Inc.144 - X4 Pharmaceuticals, Inc (0001501697) (Subject)
- PRX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on September 30, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the "2019 Inducement Plan"). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 80,000 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering i
- PRX4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare ConferenceBOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that management will participate in a fireside chat at the 2026 Wells Fargo Healthcare Conference on Thursday, September 10, 2026 at 9:30 a.m. ET. A link to the live and archived webcast may be accessed on X4 Pharmaceuticals’ website under the Investors section: Events and Presentations. About X4 Pharmaceuticals X4 Pharmaceuticals is a company focused on improving the lives of people with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unmet needs. Leveragin
- SECX4 Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - X4 Pharmaceuticals, Inc (0001501697) (Filer)
- PRX4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting- FDA Agrees to Reduced Sample Size for the Global 4WARD Phase 3 Chronic Neutropenia Trial - - Expect Completion of Enrollment by Year-End 2026 and Topline Data in H1 2028 - BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced the positive outcome of its Type C Meeting with the U.S. Food and Drug Administration (FDA) related to the global 4WARD Phase 3 clinical trial. The purpose of the meeting was to gain alignment on a revised sample size and associated statistical power and the size of the safety database to support a supplemental new drug application (sNDA) for ma
- PRX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on August 31, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the "2019 Inducement Plan"). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 50,000 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering int
- SECAmendment: SEC Form SCHEDULE 13G/A filed by X4 Pharmaceuticals Inc.SCHEDULE 13G/A - X4 Pharmaceuticals, Inc (0001501697) (Subject)
- INSIDERPresident Volpone John sold $109,228 worth of shares (24,576 units at $4.44), decreasing direct ownership by 8% to 265,305 units (SEC Form 4)4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
- INSIDERExecutive Chairman Craig Adam R sold $210,829 worth of shares (47,436 units at $4.44), decreasing direct ownership by 13% to 328,651 units (SEC Form 4)4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
- SECSEC Form 144 filed by X4 Pharmaceuticals Inc.144 - X4 Pharmaceuticals, Inc (0001501697) (Subject)
- PRX4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update- Strengthened Clinical Operations to Continue Progress in Enrolling Global 4WARD Phase 3 Chronic Neutropenia Trial - - European Commission Approval of XOLREMDI® (Mavorixafor) Provides the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union - - Balance Sheet Provides Cash Runway into 2029 - BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today reported financial results for the second quarter ended June 30, 2026 and provided a corporate update. "Since we began leading X4 last August, we have taken meaningful actions to strengthen the executio
- SECSEC Form 10-Q filed by X4 Pharmaceuticals Inc.10-Q - X4 Pharmaceuticals, Inc (0001501697) (Filer)
- PRX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on July 31, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the "2019 Inducement Plan"). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 12,000 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into e
- ANALYSTWells Fargo initiated coverage on X4 Pharmaceuticals with a new price targetWells Fargo initiated coverage of X4 Pharmaceuticals with a rating of Overweight and set a new price target of $11.00
- PRX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on July 6, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the "2019 Inducement Plan"). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 750,000 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into e
- INSIDERChief Financial Officer Kirske David sold $36,428 worth of shares (8,543 units at $4.26), decreasing direct ownership by 5% to 167,750 units (SEC Form 4)4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
- INSIDERSEC Form 4 filed by Director Gold Kelly4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
- INSIDERSEC Form 3 filed by new insider Gold Kelly3 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
- SECX4 Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - X4 Pharmaceuticals, Inc (0001501697) (Filer)
- PRX4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of DirectorsBOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced the appointment of Kelly Gold to the Company’s Board of Directors effective July 1, 2026, adding strong strategic and financial expertise. Ms. Gold will serve as an independent director and member of the Audit Committee. "We are thrilled to welcome Kelly to our Board of Directors as she brings a distinct combination of financial leadership, capital markets expertise and a scientific background," said Adam Craig, M.D., Ph.D., Executive Chairman of X4 Pharmaceuticals. "As we continue to strengthen our team to align with
XFOR FAQ
7 questionsWhat does X4 Pharmaceuticals Inc. do?
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rear diseases. Its lead product candidate is mavorixafor, an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell...Where does XFOR stock trade?
X4 Pharmaceuticals Inc. (XFOR) is listed on NASDAQ.What sector and industry is XFOR in?
X4 Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did X4 Pharmaceuticals Inc. go public?
X4 Pharmaceuticals Inc. (XFOR) completed its IPO in 2017.What are analysts saying about XFOR?
X4 Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Wells Fargo: Overweight with a $1100.00 price target on 2026-07-10.What companies are similar to XFOR?
Notable peers in the same industry include RYTM (Rhythm Pharmaceuticals Inc.), BCRX (BioCryst Pharmaceuticals Inc.), DCPH (Deciphera Pharmaceuticals Inc.). Compare XFOR side-by-side with any of them on Quantisnow.How can I track XFOR on Quantisnow?
Quantisnow aggregates X4 Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow XFOR to receive live email and push alerts on every new disclosure.